INTRODUCTION
Pulsed brachytherapy (PB) for interstitial or intraluminal irradiation is a likely successor of continuous low-dose rate (CLDR) brachytherapy, where multiple stationary radioactive sources are generally applied. By changing from continuous to pulsed irradiation, however, choices regarding the period time and the dose per pulse have to be motivated and made. Recent publications on PB describe its clinical application for a boost dose, as well as for a full irradiation course, with a period time of 1 h and a dose per pulse between 0.40 and 1.00 Gy ( Table 1) . Three of the eight institutes cited in Table 1 applied pulses Ͼ 1.00 Gy at a period time longer than 1 h.
PB irradiation with a period time of 1 h is considered to be biologically equivalent to CLDR for both early and late effects (10) . However, in vivo laboratory data comparing the biological effects of PB with CLDR are scarce. In the guinea pig, both early and late skin reaction were not distinguishable between CLDR and an hourly pulsed-irradiation regimen (11) . Equivalence was reported for cataract induction in the rat eye after exposure to 15 Gy CLDR at 0.62 Gy/h, pulsed irradiation with 0.6 Gy pulses every h, and 2.15 Gy pulses every 4 h (12). For late rectal toxicity in the rat, biological equivalence was demonstrated for PB irradiation with pulse doses up to 1.5 Gy at a period time of 2 h and CLDR at a dose rate of 0.75 Gy/h; toxicity increased with increasing pulse dose and a longer period time (13) . An advantage of PB over CLDR was reported in a rodent tumor model (14) .
In HDR brachytherapy, generally one single or a few large fractions are given, with intervals between the frac-tions exceeding 6 h (15) (16) (17) . At equal physical dosage, HDR yields a potential increase in biological effectiveness compared to CLDR. If aiming at an equivalent biological dose on late-responding normal tissue, the physical dose has to be reduced. With time intervals between the HDR fractions long enough for complete repair of sublethal damage, the repair capacity, reflected in the ␣/␤ value, is the only tissue parameter discriminating in biological effectiveness between different tissues for the same physical dose and fractionation. With time intervals shorter than 6 h in fractionated HDR however, the biological effect may be influenced by tissue-repair kinetics as well. CLDR irradiation can be considered as superfractionation with infinitesimal fraction dose and time intervals approaching zero. Hence, the biological effect of CLDR is, except for tissue-repair capacity, greatly determined by its repair kinetics.
PDR afterloaders allow a free choice of the overall treatment time, period time, and pulse dose. Nevertheless, in most modeling studies, the biological equivalence between PB and CLDR has been investigated for a restricted set of biological and physical parameters, particularly with regard to the number of pulses and period time ( Table 2) .
In the present study, radiobiological model calculations were performed for replacement of a 20 Gy CLDR boost by a PB regimen, within the benchmark of a fixed overall treatment time. Then, the period time and dose per pulse are coupled variables. The relative effectiveness was investigated for tissues with different repair capacity and repair kinetics over a range of these variables and, therewith, the number of pulses.
METHODS AND MATERIALS

Definition of terms
For physically and biologically relevant terms and abbreviations throughout this paper, the following definitions were used ( Fig. 1 
):
Nϭtotal number of pulses delivered Dϭtotal physical dose dose/pulse, DpϭD/N pulse time, T pulse ϭtime during which the dose of one pulse is delivered period time, T period ϭtime elapsed between start of pulse n and start of pulse n ϩ 1 overall treatment time, OTTϭtime between start of pulse 1 and end of pulse N T 1/2 ϭhalftime for repair of sublethal damage ␣/␤ ratioϭrepair capacity 
Radiobiological model
The biological effect of irradiation can be expressed in terms of biologically effective dose (BED) and relative effectiveness (RE), where RE is the factor relating the BED to the physical dose D, according to the equation:
(Eq. 1)
RE was calculated using the equations given below, based on the linear quadratic model for conditions of incomplete, monoexponential repair (22) (23) (24) (25) for continuous irradiation with dose rate Ḋ :
for pulsed irradiation:
where F c and F p are modifying factors between 0 and 1 expressing the influence of repair kinetics: To investigate the change in the relationship of normal tissue RE to tumor RE when switching from CLDR to PB at fixed physical dose, the behavior of the ratio (RE PB /RE CLDR ) NT /(RE PB /RE CLDR ) TUM was determined in its dependency on the number of pulses. In addition, this term was also calculated while adjusting the physical dose to keep RE PB,TUM equal to RE CLDR,TUM .
Assumptions
Cell proliferation was not taken into account because the overall treatment time was restricted to a maximum of 40 h. The time for delivery of 1 Gy was assumed to be 0.075 h (i.e., for a total dose of e.g., 20 Gy, the product of N and T pulse was fixed at 1.5 h). The biological parameters ␣/␤ and T 1/2 and the physical parameters CLDR dose rate, number of pulses, period time, and total dose used in radiobiological modeling are presented in Table 2 . Table 3 illustrates the influence of the repair parameters on the RE for different treatment regimens. A total dose of 20 Gy was assumed to be applied continuously at a dose rate of 0.50 Gy/h, 0.80 Gy/h or in 25 pulses of 0.8 Gy, or 8 pulses of 2.5 Gy (Table 3) . For all treatment regimens, the RE increases with increasing T 1/2 and decreasing ␣/␤ value.
RESULTS
Relative effectiveness of CLDR vs. PB: the influence of the ␣/␤ ratio and repair half-time
Elevating the dose rate from 0.50 Gy/h to 0.80 Gy/h, the RE increases. This change in RE is greater, the longer the T 1/2 and the lower the ␣/␤ ratio (Table 3) . Table 3 also displays the ratio of RE for continuous exposure at 0.80 Gy/h over 0.50 Gy/h to clearly illustrate that variations in ␣/␤ ratio and T 1/2 only matter for low ␣/␤ values and long repair half-times.
However, when comparing a PB regimen of 25 pulses (Table 3 ) with a regimen of 8 pulses, the greatest difference in RE is found for tissue with a short repair halftime. For example, with 25 pulses, RE values for tissue with an ␣/␤ value of 3 Gy are 1.73 at T 1/2 ϭ 1 h, 2.86 at T 1/2 ϭ 3 h, and 1.22 and 1.56 at an ␣/␤ of 10 Gy, respectively (Table 3) . With 8 pulses, the RE at an ␣/␤ value of 3 Gy amounts to 1.93 at T 1/2 ϭ 1 h and 2.84 at T 1/2 ϭ 3 h and, respectively, 1.28 and 1.55 at an ␣/␤ of 10 Gy (Table 3) .
Hence, for longer period times, the RE of a tissue with T 1/2 of 3 h remains constant, and the RE for tissue with shorter T 1/2 of, for example, 1 h shows an increase. This effect is illustrated in Table 3 , which shows the ratio on RE of a regimen with 8 pulses over a regimen with 25 pulses. The RE ratio of a tissue with long T 1/2 is almost independent on the number of pulses or length of the period time (ratio ϭ 1), but increases for tissue with short or intermediate T 1/2 (ratio Ͼ 1). This means that a relative normal tissue sparing of, for example, 10% (0.99 of 1.10) can be obtained when, instead of 25 pulses of 0.8 Gy every h, 8 pulses of 2.5 Gy every 3.4 h are delivered to normal tissue with ␣/␤ ratio of 3 Gy and T 1/2 of 3 h and to tumor with an ␣/␤ ratio of 10 Gy and a T 1/2 of 0.5 h.
The number of pulses as a function of the repair half-time
The (RE PB /RE CLDR ) NT for normal tissue (␣/␤ ratio of 3 Gy) and the (RE PB /RE CLDR ) TUM for tumor (␣/␤ ratio of 10 Gy) for application of 20 Gy in a fixed overall treatment time of 25 h in 25, 12, 8, or 4 pulses are plotted as a function of repair half-times between 0.1 and 3 h ( Fig.  2A-D) . If 25 pulses of 0.8 Gy are applied with a period time of about 1 h, the RE PB /RE CLDR is equal to 1, unless repair half-times are shorter than 0.75 h (Fig. 2A) . When assuming a longer T 1/2 for normal tissue than for tumor, the ratio (RE PB /RE CLDR ) NT / (RE PB /RE CLDR ) TUM only slightly deviates from unity. However, with a smaller number of pulses, the steepness of RE PB /RE CLDR as a function of the repair half-time increases for both normal tissue and tumor ( Figs. 2A-D) . Hence, by reducing the pulse frequency, the ratio (RE PB /RE CLDR ) NT / (RE PB / RE CLDR ) TUM becomes less than unity if normal tissue T 1/2 is longer than tumor T 1/2 . For normal tissue with a T 1/2 of 3 h (X in Fig. 2 ) and tumor with a T 1/2 of 1 h (᭛ in Fig.  2 ), these ratios decrease with increasing period times: 0.98, 0.96, 0.92, and 0.87, respectively, after 25 pulses of 0.8 Gy, 12 pulses of 1.67 Gy, 8 pulses of 2.5 Gy, or 4 pulses of 5 Gy.
The influence of variations in the ␣/␤ ratio on RE PB / RE CLDR is shown in Table 4 . With a period time of 1 h, PB has a slight advantage over CLDR (ratio Ͻ 1) at low ␣/␤ ratio and long T 1/2 and is equivalent to CLDR at high ␣/␤ ratio and intermediate T 1/2 (Table 4) . With a period time of 3.4 h, however, the slope of RE PB /RE CLDR over the range of ␣/␤ values, as well as T 1/2 , increases. Hence, a therapeutic gain might be obtained if normal tissues with low ␣/␤ ratio do have a long T 1/2 of 2-3 h and tumors with high ␣/␤ ratio do have a T 1/2 Ͻ 1.5 h ( Table 4) . Table 5 shows the RE of late-responding normal tissue and of early-responding normal tissue or tumor irradiated with 20 Gy in 2 to 25 pulses as a function of T 1/2 .
Number of pulses in a fixed overall treatment time
The table shows: (a) The gradient of RE over 4 to 25 pulses at fixed T 1/2 is greater for a tissue with an ␣/␤ ratio of 3 Gy than for a tissue with an ␣/␤ ratio of 10 Gy. For example, with a T 1/2 of 1 h, the RE gradient (4 vs. 25 pulses) is 1.47 at ␣/␤ ratio of 3 Gy, whereas this gradient is 1.20 at ␣/␤ ratio of 10 Gy. (b) On the other hand, the gradient of RE over the number of pulses at fixed ␣/␤ ratio is also dependent on the T 1/2 : it is greater in the range of 0.1 to 1 h than in the range of 1.5 to 3 h. The ratio of PB over CLDR at a dose rate of 0.80 Gy/h for normal tissue and tumor is also presented in Table 5 . Equivalence between PB and CLDR (i.e., (RE PB /RE CLDR ) NT and (RE PB /RE CLDR ) TUM equal to 1.00,) is obtained with a large number of pulses and long T 1/2 , whereas the ratios become Ͼ 1 with a small number of pulses and short T 1/2 .
The number of pulses in the PB regimen
The ratio (RE PB /RE CLDR ) NT / (RE PB /RE CLDR ) TUM as function of the number of pulses is presented in Figs. 3-5 for three different situations:
For a fixed physical dose given in a fixed overall treatment time (Fig. 3) . Irradiation with 20 Gy in 25 h in only 2 to 12 pulses will lead to a relative increase in normal tissue damage (ratio Ͼ 1) for PB in case of an equal T 1/2 of 1 h for tumor and normal tissue. However, when assuming a T 1/2 of 2 h for normal tissue, it is relatively spared with regard to CLDR irradiation due to a relative decrease in the ratio of RE (Table 5 ). This phenomenon is even more pronounced assuming a longer T 1/2 of 3 h for normal tissue, but still a T 1/2 of 1 h for the tumor ( 3). An optimum in normal tissue sparing (ϭ Ͼ 10% relative to the tumor) is then found with 3 to 6 pulses in 25 h (i.e., pulse doses between 6.67 and 3.33 Gy).
For a fixed overall treatment time, but with reduced physical dose, according to equal tumor BED (Fig. 4) . When delivering 20 Gy in less than 12 pulses, the ratio (RE PB /RE CLDR ) NT / (RE PB /RE CLDR ) TUM might exceed 1.05 (at equal T 1/2 of 1 h for both tissue types, Table 5 ). The increase in RE for tumor tissue with decreasing number of pulses requires, therefore, physical dose reduction to maintain a constant tumor control probability (i.e., (RE PB /RE CLDR ) TUM ϭ 1.00). Figure 4 shows that, applying dose reduction, the ratio (RE PB /RE CLDR ) NT / (RE PB /RE CLDR ) TUM decreases, leading to a deeper nadir (as in Fig. 3 ) than without dose reduction. The (RE PB ) NT of normal tissue with a repair half-time of 3 h is 81% of (RE CLDR ) NT if 3 pulses of 5.4 Gy are given (total physical dose of 16.3 Gy) and it is 87% with 4 pulses of 5 Gy.
For a fixed physical dose and different overall treatment time. Figure 5 shows the ratio (RE PB /RE CLDR ) NT / (RE PB / RE CLDR ) TUM as a function of the number of pulses with PB relative to CLDR at a dose rate of 0.50, 0.80, and 1.20 Gy/h (i.e., 40-, 25-, or 16.7-h exposure time for application of 20 Gy). With increasing CLDR dose rate and, thus, decreasing duration of exposure, the PB advantage is increasing and reached with fewer pulses. For example, the nadir of 0.92 is found after irradiation with 5 to 7 pulses relative to CLDR 
DISCUSSION
Tissue-repair capacity
Tissue-repair capacity (the ␣/␤ ratio) used in this study (i.e., 3 Gy for late effects and 10 Gy for early and tumor effects) are those generally accepted and used in radiobiological modeling ( Table 2) . The values of ␣/␤ for early and late reactions in human normal tissues are consistent with those obtained from animal experiments (26) . For human tumors however, ␣/␤ ratios are more variable than in animals. High values were reported for malignancies of head and neck, lung, skin, and cervix, but low values for melanomas and liposarcomas (26) .
Tissue-repair kinetics
It is still a matter of debate whether or not the rate of repair of sublethal radiation damage is different between early-and late-reacting normal tissue (27) . Repair halftimes for various normal animal tissues range from 0.3 to 2.1 h, with a tendency to slightly longer T 1/2 for late effects (28) . Recovery in human tissues might be slower than in rodents (26) . From the equality in effects between CLDR and PB irradiation of rat lens, it was concluded that the repair of sublethal damage in this late-responding tissue is quite slow (12) . Hyperfractionated radiotherapy for advanced head and neck malignancies resulted in a significant increase in late effects in patients irradiated with interfraction intervals less than 4.5 h, compared to those irradiated with intervals exceeding 4.5 h (29) . The dissociation of acute effects and tumor control from late effects suggest shorter T 1/2 for early-responding normal tissue and tumor than for late-responding normal tissue (30) . A range of estimated values for tissue repair half-times that were derived by fitting clinical data of CLDR brachytherapy and conventional external-beam radiotherapy has been described recently (20) . For tumor and early-responding normal tissue, T 1/2 most probably lies between 0.2 and 1 h and, for late effects, between 1 and 3 h.
For several normal tissues, it has been proposed that the kinetics of repair of sublethal damage may be mathematically described more precisely by a biphasic fit of the data, but the information is too diffuse yet for generalization. For moist desquamation of the epidermis of pig skin, a biexponential fit of the data resulted in an estimation of the repair half-times of 0.2 h for the fast component and 6.6 h for the slow component of repair (31, 32) . The proportion of the contribution of the fast component was estimated to be 33% (31) . However, when applying a monoexponential fit, a T 1/2 value of 1.5 h was achieved. Both early and late skin response in humans had an estimated fast component of repair with a T 1/2 of about 25 min (33) . The slow component for the early effect had an estimated T 1/2 of about 75 min and, for the late effect, this was about 250 min. The contribution of both components of repair was estimated to be 50%. Analysis of rodent spinal cord data revealed that a biexponential repair model did fit significantly better than the monoexponential model (34) . Repair half-times were A total dose of 20 Gy was assumed to be delivered in 25 h either continuously at 0.80 Gy/h or pulsed in 8 or 25 pulses.
0.7 h and 3.8 h, with the proportion of injury repaired by the longer half-time estimated to be 62%. However, after CLDR irradiation of rat spinal cord, data did fit better in a monoexponential than in a biexponential repair model, T 1/2 being 1.76 h (35) . Comparison of calculated and experimentally obtained data on repair kinetics in the mouse lip mucosa after continuous and fractionated low-dose rate irradiation also indicates that the available incomplete monoexponential repair models are applicable (36) . Short repair half-times were reported for cell lines derived from a variety of human tumors (10, 37). In a series of human cervix carcinoma cell lines, these ranged from 0.26 up to 5.7 h (38). Because repair half-times of human tissues are not well known, the present model calculations did include a range of 0.1 to 3 h.
Pulse frequency
A few large pulses and a period time of approximately 4 -12 h are calculated to be of therapeutic advantage (the nadir in Figs. 3 and 4) for the situation that normal tissue repair halftime is longer than tumor repair half-time. Such a theoretically preferential PB scheme with a few large pulses approaches currently applied fractionated HDR irradiation within a short overall treatment time. Adjusting the physical dose of PB to achieve a tumor control probability equal to CLDR, normal tissue sparing can be obtained (Fig. 4) . The explanation for the relatively increased normal tissue sparing, provided that normal tissue T 1/2 is more than twice the T 1/2 of tumor, can be found in the RE. The change of RE with decreasing number of pulses is dependent on the T 1/2 of the exposed tissue (Table 5) . At fixed ␣/␤ ratio, the change of RE with increasing dose per pulse is greater, the shorter the T 1/2 . This phenomenon is similar to the dependency of RE on the dose rate for a 2 Gy pulse as described by Fowler (39: Figs. 1 and 2) . He showed that, for one tissue at a fixed ␣/␤ ratio of 3 Gy, the relative increase in RE with increasing dose rate in the pulse is higher with a T 1/2 of 0.5 h than with a T 1/2 of 1.5 h, leading to relatively more sparing of the tissue with the longer T 1/2 . The ratio (RE PB ) NT / (RE PB ) TUM for normal tissue with an ␣/␤ ratio of 3 Gy and T 1/2 of 2-3 h and tumor with an ␣/␤ ratio of 10 Gy and T 1/2 Ͻ 1.5 h, will show even more advantages of a higher dose per pulse. However, if normal tissue and tumor have equal T 1/2 of 1 h, even with a dose reduction of 5-20% for equal tumor control, normal tissue complications will increase with decreasing number of pulses (Fig. 4) .
Regarding the uncertainty about repair half-times in human tissue, an intermediate pulse frequency (e.g., 12 pulses of 1.67 Gy every 2.3 h) might be preferential (Fig.  2B) . For replacement of a 20 Gy CLDR boost, no reduction of the total dose in PB is required, but a discriminative effect can be obtained between tissues with different repair half-times. With a longer T 1/2 for normal tissue than for tumor, such regimens would relatively spare normal tissue, which might be substantial, with a quite steep normalized dose-response gradient for late effects (40) . The beneficial effect with long T 1/2 for normal tissue relative to the tumor cannot be exploited in CLDR irradiation or in PB with a period time of 1 h ( Fig.  2A, Table 4 ). But, even in case of equal repair half-times for normal tissue and tumor, an increase in normal tissue complications would be limited. However, if tumors have long T 1/2 and late-responding tissue short T 1/2 , a considerable therapeutic loss would be obtained. In PB irradiation of tissue with short repair half-times in the order of a few min, the dose per pulse should be restricted to avoid PB/CLDR ratios of increased effect (41) .
The theoretical variation in therapeutic gain in HDR gynecological implants relative to CLDR implants was studied by Sahoo et al. (42) . Using a fixed ␣/␤ ratio and a limited range of repair half-times they derived specific conditions for which a therapeutic gain would be obtained if the tumor repair half-time were shorter than that of normal tissue. However, it was assumed that normal tissue dose was only a fraction of the tumor dose (42) .
With HDR afterloader, due to the high source activity, it is technically difficult to accurately apply doses Ͻ 2 Gy, because dwell times would become shorter than 1 s. With dwell times adjustable in tenths of a s, the dose can only be varied in steps of more than 10%. The HDR afterloader, thus, does not allow free choice of a desired pulse dose. With PB, however, in which the source activity is about 10 times lower and, hence, dwell times a few s per Gy, an appropriate dose distribution and reliable dose delivery can be obtained.
Using the assumptions given in Table 2 , Millar et al. (21) demonstrated that, for maintenance of biological equivalence between PB and CLDR, a dose reduction would be required with decreasing number of fractions from 140 to 18 for delivery of 70 Gy. The great influence of tissue-repair kinetics on the biological effect in four different pulse schemes was also discussed in their paper. A treatment regimen with two pulses of higher dose, one at the beginning and one at the end of the pulse scheme, might be another option to improve the therapeutic gain (19) . A regimen with different pulse doses cannot yet be defined as a single treatment in presently available commercial planning software.
In radiobiological modeling studies, a restriction was made to specific tissue parameters ( Table 2 ). The present calculations consider, however, a variation of repair halftimes and repair capacity of tissues, as well as the influence of the number of fractions. This allowed us to clearly distinguish the combination of parameters that cause significant changes in RE from those that only marginally influence RE (Tables 3-5 ). In addition, three different dose rates were considered (i.e., a range in overall treatment time), reflecting the actual CLDR clinical practice.
The overall treatment time
Generally, PB is considered for replacement of CLDR brachytherapy. Biological effects of PB are, therefore, often compared to those after CLDR irradiation with equal overall treatment time. Because of decaying source activity, patients treated with a new LDR source are irradiated at higher dose rates than patients treated later with the same source, leading to a range in dose rates and, hence, exposure times (43, 44) . Analysis of our own patient data showed a dose rate ranging from 0.35 to 1.20 Gy/h (mean 0.80 Gy/h). The 0.50 Gy/h dose rate generally used in radiobiological modeling (Table 2) does not cover the actual range of dose rates used in clinical treatment. The dose rate and treatment duration in CLDR experience might explain the variation in the dose per pulse and overall treatment time, leading to institutespecific PB treatment regimens ( Table 1 ). The choice of the CLDR "reference," however, influences the favorable number of pulses and amount of normal tissue sparing that might be obtained in pulsed exposure (Fig. 5) .
Extension of the overall treatment time in PB compared to CLDR, by increasing the period time while keeping the dose per pulse constant, might be another option to spare late-responding normal tissue (17) . However, except for a potential disadvantage by tumor cell repopulation, hospital implantation times have to be extended (45) and, consequently, clinical treatment capacity will decrease.
CONCLUSION
With a high number of pulses in PB, its biological effect will equal CLDR. Pulsed brachytherapy, however, offers the possibility of choosing a period time that is matched to the repair half-time of the tissues exposed. In the design of treatment protocols aiming for a therapeutic gain with pulsed brachytherapy, repair characteristics for both the target tissue and unavoidably involved normal tissues, as well as the currently used CLDR dose rate, ought to be considered. 
